Methods and low dose regimens for treating red blood cell disorders
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 31, 2013
Grant Date -
Oct 13, 2011
app pub date -
Dec 8, 2010
filing date -
Dec 8, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully